McKesson (MCK) 2024 Wells Fargo Healthcare Conference summary

Strategic acquisitions and divestitures

• Announced acquisition of Florida Cancer Specialists' business and administration services, adding 530 providers across 100 sites, enhancing scale in clinical, drug distribution, and GPO services, and expanding the iKnowMed EHR platform.

• The acquisition aligns with strategic focus on oncology and pharma services, with expected regulatory clearance pending.

• Divested Rexall and Well.ca in Canada, retaining distribution and biopharma businesses, as retail operations and online health were not strategic priorities.

• Maintains long-term distribution agreements with Rexall; the divestiture is not material to Canadian or enterprise operations for fiscal 2025.

Capital deployment and shareholder returns

• Prioritizes growth through internal development and acquisitions that fit strategic and financial criteria.

• If growth opportunities are limited, capital is returned to shareholders via dividends and share buybacks, with a recent 15% dividend increase and $4 billion share repurchase authorization.

• Guidance for $2.8 billion in share repurchases this year.

U.S. pharmaceutical business performance

• Strong customer relationships and high renewal rates drive consistent growth, especially in specialty and generics.

• Oncology platform continues to expand, with over 200 providers added last year and 58 in the first quarter.

• Notable customer win with Optum, with a smooth transition and full ramp-up starting July 1; minimal onboarding costs.

• Revenue guidance adjusted due to faster-than-expected conversion of a major specialty drug, impacting revenue but not profit.